Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 Feb 2023
Mitsubishi Tanabe Pharma Canada announces Radicava (edaravone) oral suspension is now available in Canada for the treatment of patients with ALS
10 February 2023 - Mitsubishi Tanabe Pharma Canada today announced that Radicava oral suspension, the oral formulation of Radicava IV ...
Posted by Michael Wonder on 13 Feb 2023
Amgen pricing for its Humira biosimilar may benefit PBMs and insurers more than patients
31 January 2023 - Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited discounts for its biosimilar ...
Posted by Michael Wonder on 13 Feb 2023
IASO Bio announces CT103A granted regenerative medicine advanced therapy and fast track designations by the FDA
12 February 2023 - IASO Biotherapeutics today announced that the US FDA has granted both regenerative medicine advanced therapy designation ...
Posted by Michael Wonder on 12 Feb 2023
AMA calls for two months of medicines to be dispensed from a single script
12 February 2023 - The Federal Government must show leadership and implement the recommendations of the independent PBAC to increase the ...
Posted by Michael Wonder on 11 Feb 2023
Republicans back lawsuit to overturn FDA approval of abortion pill and pull the medication from US market
10 February 2023 - 22 Republican attorneys general and 67 GOP members of Congress backed a suit seeking to overturn FDA ...
Posted by Michael Wonder on 11 Feb 2023
Digital health predictions: uncertainty will trigger innovation in 2023
7 February 2023 - It was an interesting year for digital health. ...
Posted by Michael Wonder on 11 Feb 2023
Health Canada approves Adtralza (tralokinumab) for the treatment of adolescents aged 12 to 17 with moderate to severe atopic dermatitis
8 February 2023 - Adtralza is the first treatment for adolescents with moderate to severe atopic dermatitis specifically targeting the ...
Posted by Michael Wonder on 11 Feb 2023
State of the Union highlights America’s awkward conversation on financing the development of new medicines
9 February 2023 - Science, medicine, health care, and paying for medicines featured prominently in President Joe Biden’s State of ...
Posted by Michael Wonder on 10 Feb 2023
FDA approves Pfizer's supplemental new drug application for Cibinqo (abrocitinib)
10 February 2023 - Label expansion for Cibinqo provides new systemic oral option for adolescents (12 to <18 years) with ...
Posted by Michael Wonder on 10 Feb 2023
Phathom Pharmaceuticals provides regulatory updates
9 February 2023 - Phathom Pharmaceuticals today announced regulatory updates for its approved products, Voquenza Triple Pak and Voquenza Dual Pak, ...
Posted by Michael Wonder on 10 Feb 2023
A new Alzheimer's drug gave patients hope. Millions can't get it.
10 February 2023 - Jay Reinstein, a former assistant city manager in Fayetteville, NC who was diagnosed with Alzheimer’s disease ...
Posted by Michael Wonder on 10 Feb 2023
Updates from the Health Technology Assessment Policy and Methods Review Reference Committee (February 2023)
10 February 2023 - The Health Technology Assessment Policy and Methods Review Reference Committee met on 27 January 2023. ...
Posted by Michael Wonder on 10 Feb 2023
PHARMAC to get one time $66 million boost
10 February 2023 - The national drug-buying agency will get an extra $66 million in 2023 in a one-off cash ...
Posted by Michael Wonder on 10 Feb 2023
HHS releases initial guidance for Medicare prescription drug inflation rebate program
9 February 2023 - Under President Biden’s prescription drug law, drug companies will pay rebates to the federal government for ...
Posted by Michael Wonder on 09 Feb 2023
FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer
9 February 2023 - Today, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) for adult patients with mismatch repair deficient (dMMR) recurrent ...